Who are Non arotinolol group's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ISOPROTERENOL, Norepinephrine Bitartrate In 5% Dextrose, Sotalol or Amiodarone, Intravenous amiodarone(1), Propranolol+pyridostigmine, Amiodarone Pill.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/non-arotinolol-group.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Non arotinolol group — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Non arotinolol group (Non arotinolol group) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-blocker. Area: Cardiovascular.

marketed Beta-blocker Beta-adrenergic receptors Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Non arotinolol group (Non arotinolol group) — Sumitomo Pharma (Suzhou) Co., Ltd.. Non-arotinolol group refers to beta-blockers that are structurally distinct from arotinolol, used primarily for cardiovascular conditions.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Non arotinolol group TARGET	Non arotinolol group	Sumitomo Pharma (Suzhou) Co., Ltd.	marketed	Beta-blocker	Beta-adrenergic receptors
ISOPROTERENOL	ISOPROTERENOL		marketed	Beta-adrenergic agonist	beta-adrenergic receptors	1956-01-01
Norepinephrine Bitartrate In 5% Dextrose	NOREPINEPHRINE	Pfizer	marketed	Catecholamine	alpha-adrenergic receptors, beta-adrenergic receptors	1950-01-01
Sotalol or Amiodarone	Sotalol or Amiodarone	Universitaire Ziekenhuizen KU Leuven	marketed	Class III antiarrhythmic (Sotalol); Class I/II/III/IV antiarrhythmic (Amiodarone)	Potassium channels (hERG); Beta-adrenergic receptors (Sotalol); Sodium channels, potassium channels, beta-adrenergic receptors, calcium channels (Amiodarone)
Intravenous amiodarone(1)	Intravenous amiodarone(1)	Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud	marketed	Class III antiarrhythmic agent	Potassium channels, sodium channels, calcium channels, beta-adrenergic receptors
Propranolol+pyridostigmine	Propranolol+pyridostigmine	Seoul National University Hospital	marketed	Beta-blocker + Acetylcholinesterase inhibitor combination	Beta-adrenergic receptors; Acetylcholinesterase
Amiodarone Pill	Amiodarone Pill	Our Lady of the Lake Hospital	marketed	Class III antiarrhythmic agent	Potassium channels (hERG), sodium channels, L-type calcium channels, beta-adrenergic receptors

Recent regulatory actions (last 90 days)

2026-03-26 — Norepinephrine Bitartrate In 5% Dextrose · FDA · approved · US · Pfizer

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-blocker class)

Abbott · 1 drug in this class
Centre Hospitalier Universitaire de Nice · 1 drug in this class
Grupo Argentino de Tratamiento de la Leucemia Aguda · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Sumitomo Pharma (Suzhou) Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Non arotinolol group — Competitive Intelligence Brief. https://druglandscape.com/ci/non-arotinolol-group. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing